...
首页> 外文期刊>International Journal of Hematology and Oncology >Circulating MicroRNAs in Newly Diagnosed Acute and Chronic Leukemias
【24h】

Circulating MicroRNAs in Newly Diagnosed Acute and Chronic Leukemias

机译:新诊断的急性和慢性白血病中的循环微RNA

获取原文
           

摘要

Leukemia is a clonal disease caused by genetic-epigenetic aberrations and we investigated the profile of circulating 741 microRNAs (miRNA) in plasma of newly diagnosed acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) patients compared to healthy individuals. MiRNAs are small non-coding RNA molecules and have critical roles in cell differentiation, proliferation, apoptosis. They regulate haematopoiesis in haematopoietic stem cells and committed progenitor cells, but they also play role in pathogenesis of acquired hematologic neoplasms. Recently, a growing body of evidence has implicated specific miRNAs in pathogenesis of leukemia and circulating miRNAs could serve as non-invasive biomarkers for detection of leukemia. Aim of this study was to identify miRNAs epigenetically regulated in acute and chronic leukemias. RNA was isolated using High Pure miRNA Isolation Kit (Roche) following manufacturer’s protocol. cDNA and preamplification protocols were obtained from isolated plasma miRNAs. The BioMarkTM 96.96 Dynamic Array (Fluidigm Corporation) for real-time qPCR was used to simultaneously quantite the expression of 741 miRNAs. Statistical analyses were performed using Biogazelle’s qbase PLUS 2.0 software. Among analyzed 741 miRNAs, mir-1290 and miR-548c-3p were down-regulated, mir-24-3p, miR-30b- 5p and miR-19a-3p were up-regulated in all leukemic patients comparing with control group (p< 0.05). However, in patients with ALL, mir-24-3p was significantly down-regulated and miR-548c-3p was significantly up-regulated compared to healthy subjects (p< 0.05). Our study is the first study showing the higher expression levels of miR-548c-3p in ALL. We conclude that miR-24-3p and miR-548c-3p can be used as potential biomarkers for detecting ALL.
机译:白血病是一种由基因表观遗传畸变引起的克隆性疾病,我们调查了新诊断的急性淋巴细胞白血病(ALL),急性髓细胞白血病(AML),慢性淋巴细胞性白血病(CLL),慢性的血浆中循环741 microRNA(miRNA)的概况骨髓白血病(CML)患者与健康个体相比。 MiRNA是小的非编码RNA分子,在细胞分化,增殖,凋亡中具有关键作用。它们调节造血干细胞和定型祖细胞中的造血作用,但在获得性血液肿瘤的发病机理中也发挥着作用。最近,越来越多的证据表明特定的miRNA与白血病的发病机制有关,循环中的miRNA可以作为检测白血病的非侵入性生物标记。这项研究的目的是确定在急性和慢性白血病中表观遗传调控的miRNA。按照制造商的规程,使用高纯度miRNA分离试剂盒(Roche)分离RNA。 cDNA和预扩增方案从分离的血浆miRNA中获得。用于实时qPCR的BioMarkTM 96.96动态阵列(Fluidigm Corporation)用于同时定量741个miRNA的表达。使用Biogazelle的qbase PLUS 2.0软件进行了统计分析。与对照组相比,在分析的741个miRNA中,所有白血病患者的mir-1290和miR-548c-3p均下调,mir-24-3p,miR-30b-5p和miR-19a-3p上调(p <0.05)。但是,在ALL患者中,与健康受试者相比,mir-24-3p显着下调,而miR-548c-3p显着上调(p <0.05)。我们的研究是第一个显示miR-548c-3p在ALL中较高表达水平的研究。我们得出结论,miR-24-3p和miR-548c-3p可用作检测ALL的潜在生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号